'Find Patients Who Will Respond Well to Drugs'... Dong-A ST and Cbs Biosciences Collaborate on Companion Diagnostic Technology

Dong-A ST (Dong-A ST) announced on the 31st that it has signed a joint research agreement with Cbs Bioscience for the development of companion diagnostics (CDx)-based therapeutics and the discovery of candidate substances and new drug development using a data analysis platform.

Jae-Hong Park, President of Dong-A ST R&D (left), and Jin-Young Park, CEO of Cbs Bioscience, are taking a commemorative photo at the signing ceremony of a joint research agreement for new drug development using companion diagnostics-based therapeutics and data analysis platforms.
[Photo by Dong-A ST]

Under this agreement, both companies plan to collaborate on the development of anticancer drugs and various disease treatments for hard-to-treat cancers such as triple-negative breast cancer, as well as the discovery of biomarkers, by utilizing Cbs Bioscience's companion diagnostic technology. They will also conduct joint research on biomarker and candidate substance discovery and new drug development using an artificial neural network data analysis platform.

Companion diagnostics is a technology that uses biomarkers derived from genetic testing to predict which therapeutics will be effective during the drug development stage and to select patients who are likely to respond well to the treatment after commercialization. In particular, since it allows for the selection of patient groups that can show therapeutic effects during the development stage, it can reduce risks and costs at this stage. According to the Biotechnology Innovation Organization (BIO) in the United States, the likelihood of approval (LOA) for candidate substances at the clinical phase 1 stage during the period from 2011 to 2020 was 7.9% overall, but when patients are pre-selected through biomarkers, the LOA was analyzed to increase up to 15.9%.

Cbs Bioscience is said to possess companion diagnostic technology that can select patient groups responsive to specific anticancer drugs by utilizing big data and artificial intelligence (AI). Using its self-developed artificial neural network data analysis platform, it has discovered biomarkers in liver cancer, triple-negative breast cancer, and rectal cancer. It holds clinical and genomic big data through more than 10 years of domestic and international joint clinical research.

Jinyoung Park, CEO of Cbs Bioscience, said, "If Dong-A ST's expertise in new drug development and Cbs Bioscience's specialized biomarker discovery technology converge, it will create mutual synergy, accelerate research and development speed, and become a breakthrough opportunity to contribute to the success of clinical trials."

Jaehong Park, President of R&D at Dong-A ST, also said, "Through this agreement, we will establish a successful new drug development cooperation model between domestic pharmaceutical companies and bio venture firms. We will strive to produce excellent research outcomes by utilizing Cbs Bioscience's biomarker discovery technology and data analysis platform."

This content was produced with the assistance of AI translation services.